Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Some medtech stocks did decline in 2018, but many more increased in value.
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Big medtech is keeping its purse-strings closed – but private equity sees value in subsidiaries.
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.